Bladder Preservation for Muscle-Invasive Bladder Cancer With Variant Histology

Partial cystectomy for bladder squamous cell carcinoma with a 10-year follow-up: a case report

“…A report by Brocklehurst et al. ( 3 ) confirmed the excellent efficacy of bladder preservation in small cell carcinoma of non-UC. However, SCC is not supported by good evidence.…”

“…The disease is more common in men than in women. At this stage, the incidence rate tends to be stable or decreasing in men but is increasing year by year in women ( 2 , 3 ). Depending on histological sources, 90%–95% of bladder cancers originate from urothelial carcinoma, which is called transitional cell carcinoma.…”

“…( 11 ) showed that only a quarter of patients with SCC were positive for circulating tumor cells. Another report showed a sensitivity of only 39% for transurethral resection of bladder tumors (TURBT) ( 3 ). It is important to note that multi-site mucosal biopsy can reduce the chance of missed or even misdiagnosis.…”

Long-Term Survival After Definitive Concurrent Chemoradiation Therapy for Synchronous Small Cell Neuroendocrine Carcinoma of the Urinary Bladder and Adenocarcinoma of the Prostate: A Case Report

“…Liu et al reported two cases of synchronous SCCB and prostate adenocarcinoma managed curatively with upfront radical cystoprostatectomy and adjuvant chemotherapy (carboplatin/etoposide), with one patient dying at nine months and one alive at 19 months follow-up [ 7 ]. Non-urothelial or non-transitional cell histology is found in 53%-55% of bladder cancers, with squamous cells (45%) and micropapillary (26%) comprising the majority of variant histology [ 8 , 9 ]. SCCB is an aggressive and rare diagnosis, with an annual incidence of 0.03 to 0.14 per 100,000 persons, accounting for 0.7%-1% of all bladder cancer diagnoses and conferring the worst prognosis of all bladder cancer histology, with 37% of cases presenting with nodal or distant metastases at diagnosis, compared to 13.6% for urothelial carcinoma [ 1 , 2 ].…”

“…A large multicentre British study reported similar survival outcomes between surgery and radiation [ 15 ]. Prophylactic cranial irradiation is controversial [ 9 ]. A small prospective phase 2 trial reported a 50% risk of developing brain metastases in patients with bulky primary or metastatic disease at diagnosis [ 17 ], but in two larger series, only 1.5%-3% of all patients with localized disease at diagnosis experienced intracranial progression [ 14 , 16 ].…”